Madrasin

SKU: orb1223134

Description

Madrasin is a potent and cell penetrant splicing inhibitor that interferes with the early stages of spliceosome assembly. Madrasin stalls spliceosome assembly at the A complex.(In Vitro):Madrasin (10-30 μM; 4-24 hours; HeLa cells) treatment inhibits the splicing of each of the RIOK3, BRD2, and Hsp40, MCL1, CCNA2, AURKA and p27 pre-mRNAs in both HeLa and HEK293 cells.Madrasin (10-30 μM; 4-24 hours; HeLa and HEK293 cells) treatment shows a dose- and time-dependent inhibitory effect on cell cycle progression.

Key Properties

• CAS Number: 374913-63-0
• MW: 311.34
• Purity: >98% (HPLC)
• Formula: C₁₆H₁₇N₅O₂
• SMILES: O=c1[nH]c(Nc2nc(C)c3ccc(OC)cc3n2)nc(C)c1C
• Target: Transferase
• Solubility: H2O : < 0.1 mg/mL

Bioactivity

• In Vitro:
  Madrasin (10-30 μM; 4-24 hours; HeLa cells) treatment inhibits the splicing of each of the RIOK3, BRD2, and Hsp40, MCL1, CCNA2, AURKA and p27 pre-mRNAs in both HeLa and HEK293 cells. Madrasin (10-30 μM; 4-24 hours; HeLa and HEK293 cells) treatment shows a dose- and time-dependent inhibitory effect on cell cycle progression. RT-PCR Cell line: HeLa cells. Concentration: 10 μM, 20 μM, or 30 μM. Incubation time: 4 hours, 8 hours, or 24 hours. Result: Increased in inhibition of pre-mRNA splicing. Cell Cycle Analysis Cell line: HeLa and HEK293 cells. Concentration: 10 μM, 20 μM, or 30 μM. Incubation time: 4 hours, 8 hours, or 24 hours. Result: In the presence of 10 μM 8 hours after treatment, the proportion of cells in G2, M, and S phases increased, with a concomitant decrease in the number of G1 phase cells. This effect increased over time, with > 40% of cells in G2 and M phase and > 50% in S phase 24 hours.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

DDD00107587 | Madrasin. RNA splicing inhibitor

Quick Database Links

Gene Symbol

Transferase